admin – Page 3570 – Get News Story

Systemic Lupus Erythematosus Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

“Systemic Lupus Erythematosus Treatment Market”

Systemic Lupus Erythematosus companies are GlaxoSmithKline, AstraZeneca, Sanofi, Eli Lilly/Nektar Therapeutics, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Alpine Immune Sciences, Johnson & Johnson (Janssen), Idorsia Pharmaceuticals, Resolve Therapeutics, Amgen, AbbVie, Novartis, Corestem, Horizon Therapeutics, Boston Pharmaceuticals, InnoCare Pharma, Equillium, Merck, Gilead sciences, I-Mab Biopharma/MorphoSys AG, Chipscreen Biosciences, and others.

(New York, USA) DelveInsight’s “Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Systemic Lupus Erythematosus market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Systemic Lupus Erythematosus market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Systemic Lupus Erythematosus treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Systemic Lupus Erythematosus market.

Request for a Free Sample Report @ Systemic Lupus Erythematosus Market Forecast

Some facts of the Systemic Lupus Erythematosus Market Report are:

According to DelveInsight, Systemic Lupus Erythematosus market is expected to grow at a decent CAGR by 2034.
The Systemic Lupus Erythematosus Market Size in the 7MM was around USD 3,200 million in 2023.
Leading Systemic Lupus Erythematosus companies working in the market are GlaxoSmithKline, AstraZeneca, Sanofi, Eli Lilly and Company/Nektar Therapeutics, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Alpine Immune Sciences, Johnson & Johnson (Janssen), Idorsia Pharmaceuticals, Resolve Therapeutics, Amgen, AbbVie, Novartis, Corestem, Horizon Therapeutics, Boston Pharmaceuticals, InnoCare Pharma, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma/MorphoSys AG, Chipscreen Biosciences, and others.
Key Systemic Lupus Erythematosus Therapies expected to launch in the market are Dapirolizumab pegol, BIIB059, Obinutuzumab (Gazyva/Gazyvaro), IPP-201101 (Lupuzor), and others.
Systemic Lupus Erythematosus market size increment is a direct consequence of expected entry of promising emerging therapies, increasing awareness of the disease, and recent advancements in research and development in the 7MM.
In April 2025, AstraZeneca announced results of a Phase III, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Moderate to Severe Active Systemic Lupus Erythematosus (SLE) While on Background Standard of Care Therapy
In February 2025, Adicet Bio revealed that its experimental allogeneic CAR-engineered gamma delta T-cell therapy, ADI-100, was granted Fast Track designation by the FDA for treating refractory systemic lupus erythematosus (SLE) with extrarenal manifestations. This therapy had previously received the same designation for relapsed or refractory class III or IV lupus nephritis (LN).
In March 2025, Novartis announced a Randomized, Double-blind, Placebo-controlled Extension Study to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
In March 2025, GlaxoSmithKline announced a Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus
In February 2025, the FDA approved Allogene Therapeutics’ investigational new drug (IND) application for ALLO-329, an allogeneic CAR-T cell therapy. The company plans to initiate the Phase 1 RESOLUTION trial by mid-2025 to evaluate its potential in treating autoimmune disorders such as systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathies, and systemic sclerosis.
In December 2024, Novartis announced a Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
In May 2024, the US FDA approved a 200 mg subcutaneous route of administration of BENLYSTA for patients five years of age and older with active SLE who are receiving standard therapy. This option provides pediatric patients the possibility to receive the treatment at home.

Systemic Lupus Erythematosus Overview

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissues and organs. Systemic Lupus Erythematosus primarily affects the skin, joints, kidneys, brain, and other vital organs, leading to widespread inflammation and damage. Systemic Lupus Erythematosus symptoms vary widely but commonly include fatigue, joint pain, skin rashes, and fever. Systemic Lupus Erythematosus can range from mild to life-threatening, depending on organ involvement and disease progression.

Systemic Lupus Erythematosus is more prevalent in women, especially during childbearing years, and can be triggered by genetic, hormonal, and environmental factors. Systemic Lupus Erythematosus diagnosis involves a combination of blood tests, clinical evaluations, and imaging studies. There is no cure for Systemic Lupus Erythematosus, but early intervention and tailored treatment plans can significantly improve quality of life.

Systemic Lupus Erythematosus treatment typically includes immunosuppressive drugs, corticosteroids, and biologics to reduce inflammation and prevent flares. Recent advancements in Systemic Lupus Erythematosus research have led to the development of targeted therapies and innovative clinical trials. Understanding Systemic Lupus Erythematosus pathophysiology is essential for improving outcomes and identifying effective therapies. Raising awareness about Systemic Lupus Erythematosus can lead to earlier diagnosis and better disease management.

Learn more about Systemic Lupus Erythematosus treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Systemic Lupus Erythematosus Treatment Market

Systemic Lupus Erythematosus Market

The Systemic Lupus Erythematosus market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Systemic Lupus Erythematosus market trends by analyzing the impact of current Systemic Lupus Erythematosus therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Systemic Lupus Erythematosus market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Systemic Lupus Erythematosus market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The Systemic Lupus Erythematosus (SLE) market is driven by several key factors, including a rising prevalence of autoimmune disorders, increased awareness and diagnosis rates, and advancements in biologic and targeted therapies. The growing investment in research and development, particularly in novel immunotherapies and CAR-T cell therapies, has significantly expanded the therapeutic landscape. Furthermore, regulatory incentives such as orphan drug and fast track designations for SLE treatments have accelerated drug development and market entry. Strategic collaborations between biotech firms and pharmaceutical companies are also fostering innovation in the Systemic Lupus Erythematosus market.

However, despite these drivers, the Systemic Lupus Erythematosus market faces notable barriers. The complexity and heterogeneity of the disease present challenges in clinical trial design, biomarker identification, and personalized treatment approaches. Additionally, the high cost of biologics and advanced therapies limits access in certain regions, especially in low- and middle-income countries. Limited awareness among healthcare professionals in underdeveloped areas and diagnostic delays can also hinder timely intervention. Moreover, safety concerns and long-term side effects associated with immunosuppressive treatments remain a significant constraint. Addressing these challenges is crucial for unlocking the full potential of the Systemic Lupus Erythematosus market and improving patient outcomes worldwide.

According to DelveInsight, the Systemic Lupus Erythematosus market in 7MM is expected to witness a major change in the study period 2020-2034.

Systemic Lupus Erythematosus Epidemiology

The Systemic Lupus Erythematosus epidemiology section provides insights into the historical and current Systemic Lupus Erythematosus patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Systemic Lupus Erythematosus market report also provides the diagnosed patient pool, trends, and assumptions.

Systemic Lupus Erythematosus Epidemiology Segmentation:

Total Diagnosed Prevalent Population of Systemic Lupus Erythematosus
Gender-specific Diagnosed Prevalent Population of Systemic Lupus Erythematosus
Age-specific Diagnosed Prevalent Population of Systemic Lupus Erythematosus
Severity-specific Diagnosed Prevalent Population of Systemic Lupus Erythematosus

Explore more about Systemic Lupus Erythematosus Epidemiology @ Systemic Lupus Erythematosus Patient Population

Systemic Lupus Erythematosus Drugs Uptake

This section focuses on the uptake rate of the potential Systemic Lupus Erythematosus drugs recently launched in the Systemic Lupus Erythematosus market or expected to be launched in 2020-2034. The analysis covers the Systemic Lupus Erythematosus market uptake by drugs, patient uptake by therapies, and sales of each drug.

Systemic Lupus Erythematosus Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Systemic Lupus Erythematosus market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Systemic Lupus Erythematosus Pipeline Therapies and Key Companies

Itolizumab: Equillium/Biocon Limited
ICP-022: InnoCare Pharma
BOS161721: Boston Pharmaceuticals
NKTR-358: Nektar Therapeutics/Eli Lilly
ABBV-599: AbbVie
Deucravacitinib: Bristol Myers Squibb
BIIB059: Biogen
Gazyva/Gazyvaro (Obinutuzumab): Hoffman-La-Roche
Lupuzor: ImmuPharma
SAR441344: Sanofi

Request for a sample report to understand more about the Systemic Lupus Erythematosus pipeline development activities @ Systemic Lupus Erythematosus Companies and Medication

Systemic Lupus Erythematosus Therapeutics Assessment

Major key companies are working proactively in the Systemic Lupus Erythematosus Therapeutics market to develop novel therapies which will drive the Systemic Lupus Erythematosus treatment markets in the upcoming years are GlaxoSmithKline (LSE: GSK), AstraZeneca (LSE: AZN), Sanofi (EPA: SAN), Eli Lilly and Company (NYSE: LLY), Nektar Therapeutics (NASDAQ: NKTR), UCB Pharma (EBR: UCB), Hoffmann-La Roche (SWX: ROG), Biogen (NASDAQ: BIIB), ImmuPharma (LSE: IMM), Xencor (NASDAQ: XNCR), Bristol Myers Squibb (NYSE: BMY), Alpine Immune Sciences (NASDAQ: ALPN), Johnson & Johnson (NYSE: JNJ), Idorsia Pharmaceuticals (SWX: IDIA), Resolve Therapeutics (Private), Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), Novartis (SWX: NOVN), Corestem (KOSDAQ: 317690), Horizon Therapeutics (NASDAQ: HZNP), Boston Pharmaceuticals (Private), InnoCare Pharma (HKEX: 9969), Landos Biopharma (NASDAQ: LABP), Equillium (NASDAQ: EQ), Merck Healthcare KGaA (XETRA: MRK), Gilead Sciences (NASDAQ: GILD), I-Mab Biopharma (NASDAQ: IMAB), MorphoSys AG (XETRA: MOR), Chipscreen Biosciences (SHE: 688321), and others.

Learn more about the emerging Systemic Lupus Erythematosus therapies & key companies @ Systemic Lupus Erythematosus Clinical Trials and Pipeline Analysis

Systemic Lupus Erythematosus Report Key Insights

1. Systemic Lupus Erythematosus Patient Population

2. Systemic Lupus Erythematosus Market Size and Trends

3. Key Cross Competition in the Systemic Lupus Erythematosus Market

4. Systemic Lupus Erythematosus Market Dynamics (Key Drivers and Barriers)

5. Systemic Lupus Erythematosus Market Opportunities

6. Systemic Lupus Erythematosus Therapeutic Approaches

7. Systemic Lupus Erythematosus Pipeline Analysis

8. Systemic Lupus Erythematosus Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Systemic Lupus Erythematosus Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Systemic Lupus Erythematosus Competitive Intelligence Analysis

4. Systemic Lupus Erythematosus Market Overview at a Glance

5. Systemic Lupus Erythematosus Disease Background and Overview

6. Systemic Lupus Erythematosus Patient Journey

7. Systemic Lupus Erythematosus Epidemiology and Patient Population

8. Systemic Lupus Erythematosus Treatment Algorithm, Current Treatment, and Medical Practices

9. Systemic Lupus Erythematosus Unmet Needs

10. Key Endpoints of Systemic Lupus Erythematosus Treatment

11. Systemic Lupus Erythematosus Marketed Products

12. Systemic Lupus Erythematosus Emerging Therapies

13. Systemic Lupus Erythematosus Seven Major Market Analysis

14. Attribute Analysis

15. Systemic Lupus Erythematosus Market Outlook (7 major markets)

16. Systemic Lupus Erythematosus Access and Reimbursement Overview

17. KOL Views on the Systemic Lupus Erythematosus Market

18. Systemic Lupus Erythematosus Market Drivers

19. Systemic Lupus Erythematosus Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Lupus Erythematosus Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

NLRP3 Protein Inhibitors Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsigh

“NLRP3 Protein Inhibitors Clinical Trials”

NLRP3 protein inhibitors companies are Halia Therapeutics, Ventus Therapeutics, EpicentRx, Zydus Lifesciences Limited, Monte Rosa Therapeutics, Inflammasome Therapeutics, Ventyx Biosciences, Biolexis Therapeutics, Halia Therapeutics, Olatec Therapeutics, Secarna Pharmaceuticals, Novo Nordisk, NodThera, and others.

(Albany, USA) DelveInsight’s ‘NLRP3 Protein Inhibitors Pipeline Insight 2025’ report provides comprehensive global coverage of pipeline NLRP3 protein inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the NLRP3 protein inhibitors pipeline domain.

The potential for NLRP3 inhibitors extends beyond autoimmune and inflammatory diseases. Ongoing research suggests they may also be effective in treating neurodegenerative diseases like Alzheimer’s, Parkinson’s, and multiple sclerosis, as well as metabolic conditions like gout and non-alcoholic steatohepatitis (NASH). This broad range of applications is driving market interest.

The NLRP3 protein inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage NLRP3 protein inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the NLRP3 protein inhibitors clinical trial landscape.

Request for sample report @ NLRP3 Protein Inhibitors Clinical Trials and Pipeline Outlook

Key Takeaways from the NLRP3 Protein Inhibitors Pipeline Report

DelveInsight’s NLRP3 protein inhibitors pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline NLRP3 protein inhibitors.
Key NLRP3 protein inhibitors companies such as Halia Therapeutics, Ventus Therapeutics, EpicentRx, Zydus Lifesciences Limited, Monte Rosa Therapeutics, Inflammasome Therapeutics, Ventyx Biosciences, Biolexis Therapeutics, Halia Therapeutics, Olatec Therapeutics, Secarna Pharmaceuticals, Novo Nordisk, NodThera, and others are evaluating new NLRP3 protein inhibitors drugs to improve the treatment landscape.
Promising pipeline NLRP3 protein inhibitors such as HT6184, VENT 02, Nibrozetone, ZYIL1, MRT-8102, Kamuvudine-9, VTX 3232, NLRP3 inflammasome inhibitor, Dapansutrile, NNC6022-0001, NLRP3 Research Program, NT 0796, and others are under different phases of NLRP3 protein inhibitors clinical trials.
In August 2024, Halia Therapeutics and Biolexis Therapeutics announced an ongoing collaboration that successfully identified a novel brain-penetrant small molecule candidate targeting NLRP3-driven neuroinflammation by leveraging Biolexis’ MolecuLern™ AI-enabled approach. This milestone represents a significant advancement in developing treatments for neuroinflammatory disorders, including Parkinson’s disease and other neurodegenerative conditions.
In June 2024, NodThera announced positive data from its Phase Ib/IIa cardiovascular risk study in inflamed obese subjects, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory, cardiovascular and metabolic risk parameters.
In May 2024, Novo Nordisk successfully dosed the first participant in a Phase I clinical study for NNC6022-0001 (formerly known as VENT-01) – an oral NLRP3 inhibitor licensed by Novo Nordisk in September 2022.
In April 2024, Ventus Therapeutics announced results from its Phase I clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor. The Phase I trial evaluated the pharmacodynamics, pharmacokinetics, safety, and tolerability of VENT-02 across a broad range of single and multiple ascending doses in adult healthy volunteers.
In March 2024, Parkinson’s UK announced the investment of GBP 2.1 million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to reduce inflammation and protect brain cells in Parkinson’s.

Request a sample and discover the recent advances in NLRP3 protein inhibitors drugs @ NLRP3 Protein Inhibitors Pipeline Report

NLRP3 Protein Inhibitors Overview

NOD-like receptor family pyrin domain-containing 3 (NLRP3) protein is a key component of the innate immune system, playing a crucial role in the activation of the inflammasome. The NLRP3 inflammasome is responsible for the maturation and release of pro-inflammatory cytokines such as IL-1β and IL-18. This process is essential for host defense against pathogens but can lead to chronic inflammation when dysregulated. Overactivation of the NLRP3 inflammasome is implicated in a wide range of diseases, including autoimmune disorders, metabolic syndromes, neurodegenerative diseases, and certain cancers. Thus, targeting NLRP3 with specific inhibitors has become a promising strategy for treating these inflammatory conditions.

NLRP3 protein inhibitors work by either directly blocking the NLRP3 protein or interfering with its activation pathway, thereby preventing the assembly of the inflammasome and subsequent cytokine release. These inhibitors offer a novel therapeutic approach by addressing the root cause of inflammation rather than merely managing its symptoms. Several NLRP3 inhibitors are currently under development, with some already in clinical trials for diseases like gout, rheumatoid arthritis, and type 2 diabetes. Their ability to modulate the inflammatory response makes them a potential game-changer in the treatment of chronic inflammatory diseases, offering hope for more effective and targeted therapies.

Find out more about NLRP3 protein inhibitors drugs @ NLRP3 Protein Inhibitors Drugs Analysis

A snapshot of the Pipeline NLRP3 Protein Inhibitors Drugs mentioned in the report:

Nibrozetone: EpicentRx
ZYIL 1: Zydus Cadila
HT6184: Halia Therapeutics
VTX 3232: Ventyx Biosciences
VENT 02: Ventus Therapeutics
NNC6022-0001: Novo Nordisk
Kamuvudine-9: Inflammasome Therapeutics
MRT-8102: Monte Rosa Therapeutics

Learn more about the emerging NLRP3 protein inhibitors @ NLRP3 Protein Inhibitors Medication and FDA approval

NLRP3 Protein Inhibitors Therapeutics Assessment

The NLRP3 protein inhibitors pipeline report proffers an integral view of the emerging NLRP3 protein inhibitors segmented by stage, product type, molecule type, and route of administration.

Scope of the NLRP3 Protein Inhibitors Pipeline Report

Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Infusion, Intradermal, Intramuscular, Intranasal, Intravaginal, Oral, Parenteral, Subcutaneous, Topical
Therapeutics Assessment By Molecule Type: Vaccines, Monoclonal antibody, Peptides, Polymer, Small molecule
Key NLRP3 Protein Inhibitors Companies: Monte Rosa Therapeutics (NASDAQ: GLUE), Ventyx Biosciences (NASDAQ: VTYX), Zydus Lifesciences Limited (BSE: 532321, NSE: ZYDUSLIFE), and Novo Nordisk (NYSE: NVO, OMX: NOVO-B), Halia Therapeutics, Ventus Therapeutics, EpicentRx, Inflammasome Therapeutics, Biolexis Therapeutics, Olatec Therapeutics, Secarna Pharmaceuticals, and NodThera, and others
Key NLRP3 Protein Inhibitors Pipeline Therapies: HT6184, VENT 02, Nibrozetone, ZYIL1, MRT-8102, Kamuvudine-9, VTX 3232, NLRP3 inflammasome inhibitor, Dapansutrile, NNC6022-0001, NLRP3 Research Program, NT 0796, and others

Dive deep into rich insights for new NLRP3 protein inhibitors, visit @ NLRP3 Protein Inhibitors Therapies and Drugs

Table of Contents

1. NLRP3 Protein Inhibitors Pipeline Report Introduction

2. NLRP3 Protein Inhibitors Pipeline Report Executive Summary

3. NLRP3 Protein Inhibitors Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. NLRP3 Protein Inhibitors Clinical Trial Therapeutics

6. NLRP3 Protein Inhibitors Pipeline: Late-Stage Products (Pre-registration)

7. NLRP3 Protein Inhibitors Pipeline: Late-Stage Products (Phase III)

8. NLRP3 Protein Inhibitors Pipeline: Mid-Stage Products (Phase II)

9. NLRP3 Protein Inhibitors Pipeline: Early-Stage Products (Phase I)

10. NLRP3 Protein Inhibitors Pipeline Therapeutics Assessment

11. Inactive Products in the NLRP3 Protein Inhibitors Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Companies

14. Key Products in the NLRP3 Protein Inhibitors Pipeline

15. Unmet Needs

16. Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NLRP3 Protein Inhibitors Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsigh

MASH Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Patient Pool, MOA, ROA and Companies by DelveInsight

“MASH Drugs Market”

MASH Companies are Hepion Pharmaceuticals, Ionis Pharmaceuticals, Galectin Therapeutics, Novo Nordisk A/S, Cirius Therapeutics, HighTide Biopharma, Boehringer Ingelheim, Hepagene, Eli Lilly and Company, Pfizer, Lipocine, Corcept Therapeutics, Poxel SA, Enyo Pharmaceuticals, Akero Therapeutics, Zydus Therapeutics, 89bio, Viking Therapeutics, Boston Pharmaceuticals, Gilead Sciences, Merck & Co., Zealand Pharma, Hanmi Pharmaceutical, Inventiva Pharma, CytoDyn, Sagimet Biosciences, and others.

(Albany, USA) DelveInsight’s Metabolic Dysfunction-Associated Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, MASH emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

The MASH market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted MASH market size from 2020 to 2034, segmented by seven major markets. The Report also covers current MASH treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the MASH market.

Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report

The total MASH market size in the 7MM was approximately USD 2,114 million in 2023 and is projected to increase during the forecast period (2024–2034).

In 2023, there were an estimated 42 million prevalent cases of MASH in the 7MM. Out of these, a total of ~15 million cases were diagnosed, and this number is projected to increase by the end of 2034 in the 7MM.
Leading MASH companies such as Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, and others are developing novel MASH drugs that can be available in the MASH market in the coming years.
The promising MASH therapies in the pipeline include Lanifibranor (IVA337), Semaglutide, Azemiglitazone (MSDC-0602K), Efruxifermin (EFX), BIO89-100 (Pegozafermin), Survodutide (BI 456906), GR-MD-02 (Belapectin), LPCN1144, VK2809, Tirzepatide, BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), HTD1801, Leronlimab (PRO 140), Efinopegdutide, HPG1860, Rencofilstat (CRV431), EYP001 (Vonafexor), Semaglutide/Cilofexor/Firsocostat, PXL065, Saroglitazar Magnesium, Denifanstat (TVB-2640), ION224, Miricorilant (CORT118335), and others.
In March 2024, Madrigal Pharmaceuticals’ groundbreaking product, REZDIFFRA (resmetirom), a once-daily, oral THR-ß agonist, received accelerated endorsement from the US FDA based on results from the Phase III MAESTRO-NASH trial. This approval marks a significant stride in the medical landscape, as REZDIFFRA becomes the inaugural and sole FDA-sanctioned therapy for adults afflicted with non-cirrhotic MASH, accompanied by moderate to advanced liver scarring (fibrosis) corresponding to stages F2–F3 fibrosis.

Discover which therapies are expected to grab the major MASH market share @ Metabolic Dysfunction-Associated Steatohepatitis Market Report

Metabolic Dysfunction-Associated Steatohepatitis Overview

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that stems from metabolic dysfunction, often linked to obesity, diabetes, and other conditions of metabolic syndrome. MASH is characterized by the accumulation of fat in liver cells, accompanied by inflammation and liver cell injury, which can progress to fibrosis, cirrhosis, or even liver cancer.

The primary drivers of MASH include insulin resistance, obesity, type 2 diabetes, and dyslipidemia. Genetic predisposition and a sedentary lifestyle also play significant roles. Environmental factors, such as a poor diet high in sugars and fats, exacerbate the condition.

MASH is often asymptomatic in its early stages. When MASH symptoms occur, they can include fatigue, vague abdominal discomfort, or pain in the upper right quadrant. In advanced stages, signs of liver dysfunction such as jaundice, swelling of the abdomen or legs, and confusion may arise.

MASH Diagnosis involves a combination of clinical history, physical examination, and diagnostic tests. Blood tests measuring liver enzymes (ALT, AST) often indicate liver inflammation. Imaging techniques like ultrasound, MRI, or FibroScan can identify liver fat and fibrosis. In some cases, a liver biopsy is required to confirm the diagnosis and assess disease severity.

Metabolic Dysfunction-Associated Steatohepatitis Epidemiology Segmentation

The MASH epidemiology section provides insights into the historical and current MASH patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The MASH market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Prevalent Cases of MASH
Diagnosed Prevalent Cases of MASH
Gender-specific Diagnosed Prevalent Cases of MASH
Severity-specific Diagnosed Prevalent Cases of MASH

MASH Treatment Market

The approval of REZDIFFRA (resmetirom) in March 2024 represents a pivotal achievement in medical innovation, transforming the treatment landscape for MASH disease. This groundbreaking therapy addresses the root causes of MASH, offering renewed hope to patients grappling with this challenging condition. Clinical trials have shown impressive results, with REZDIFFRA effectively reducing symptoms like inflammation and fibrosis, enhancing liver function, and improving patients’ quality of life. By providing healthcare professionals with a robust treatment option, this approval addresses a critical unmet need and has the potential to significantly alleviate the complications linked to advanced liver disease.

The prevalence of MASLD is strongly linked to type 2 diabetes mellitus and obesity, particularly in individuals with a higher body mass index. However, MASLD occurrence is reduced in T2DM patients receiving treatments such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, GLP-1 receptor agonists, and insulin. Vitamin E, with its antioxidant properties, is regarded as a first-line pharmacological option for managing MASH, especially when dietary and lifestyle interventions are insufficient.

To know more about MASH treatment guidelines, visit @ Metabolic Dysfunction-Associated Steatohepatitis Management

Metabolic Dysfunction-Associated Steatohepatitis Pipeline Therapies and Key Companies

Lanifibranor (IVA337): Inventiva Pharma
Semaglutide: Novo Nordisk A/S
Azemiglitazone (MSDC-0602K): Cirius Therapeutics
Efruxifermin (EFX): Akero Therapeutics
BIO89-100 (Pegozafermin): 89bio
Survodutide (BI 456906): Boehringer Ingelheim/Zealand Pharma
GR-MD-02 (Belapectin): Galectin Therapeutics
LPCN1144: Lipocine
VK2809: Viking Therapeutics
Tirzepatide: Eli Lilly and Company
BOS-580: Boston Pharmaceuticals
Ervogastat (PF-06865571) + Clesacostat (PF-05221304): Pfizer
HTD1801: HighTide Biopharma
Leronlimab (PRO 140): CytoDyn
Efinopegdutide: Merck & Co./Hanmi Pharmaceutical
HPG1860: Hepagene (Shanghai)
Rencofilstat (CRV431): Hepion Pharmaceuticals
EYP001 (Vonafexor): Enyo Pharmaceuticals
Semaglutide/ Cilofexor/ Firsocostat: Gilead Sciences
PXL065: Poxel SA
Saroglitazar Magnesium: Zydus Therapeutics
Denifanstat (TVB-2640): Sagimet Biosciences
ION224: Ionis Pharmaceuticals
Miricorilant (CORT118335): Corcept Therapeutics

Discover more about MASH drugs in development @ Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials and Advancements

MASH Market Dynamics

The MASH market dynamics are expected to change in the coming years. Growing research activities and multiple clinical trials for MASH, driven by the rapid surge in its prevalence due to rising obesity and type 2 diabetes rates, highlight an active drug development pipeline and an expanding market size. The large pool of patients and lucrative growth opportunities present attractive prospects for key players, further supported by ongoing preclinical studies aimed at advancing imaging techniques for MASH diagnosis, potentially eliminating the need for invasive biopsy-based histopathological confirmation.

Furthermore, potential therapies are being investigated for the treatment of MASH, and it is safe to predict that the treatment space will significantly impact the MASH market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the MASH market in the 7MM.

However, several factors may impede the growth of the MASH market. Lack of awareness and negligence in the early stages of MASH by physicians often lead to disease progression, culminating in irreversible damage where liver transplantation becomes the only viable option. Diagnosing advanced MASH typically requires procedures like liver biopsy, which are costly, invasive, and risky. Regulatory challenges also pose hurdles, as the FDA mandates achieving one MASH endpoint for approval, while the EMA’s draft guidance requires efficacy in both endpoints, potentially delaying first-mover approvals in major European markets. Additionally, access to expensive MASH treatments may be limited in certain regions, further hindering patient adoption.

Moreover, MASH treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, MASH market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact MASH market growth.

Download the report to understand which factors are driving MASH drugs and therapies in pipeline @ Metabolic Dysfunction-Associated Steatohepatitis Treatment Market

Scope of the Metabolic Dysfunction-Associated Steatohepatitis Market Report

Study Period: 2020–2034
Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Metabolic Dysfunction-Associated Steatohepatitis CAGR: 17.9 %
Metabolic Dysfunction-Associated Steatohepatitis Market Size in 2023: USD 2.1 Billion
Key Metabolic Dysfunction-Associated Steatohepatitis Companies: Hepion Pharmaceuticals (NASDAQ: HEPG), Ionis Pharmaceuticals (NASDAQ: IONS), Galectin Therapeutics (NASDAQ: GALT), Novo Nordisk A/S (NYSE: NVO), Cirius Therapeutics (Private), HighTide Biopharma (TSX-V: HBT), Boehringer Ingelheim (Private), Hepagene (Private), Eli Lilly and Company (NYSE: LLY), Pfizer (NYSE: PFE), Lipocine (NASDAQ: LPCN), Corcept Therapeutics (NASDAQ: CORT), Poxel SA (EPA: POXEL), Enyo Pharmaceuticals (Private), Akero Therapeutics (NASDAQ: AKRO), Zydus Therapeutics (NSE: ZYDUSLIFE), 89bio (NASDAQ: ETNB), Viking Therapeutics (NASDAQ: VKTX), Boston Pharmaceuticals (Private), Gilead Sciences (NASDAQ: GILD), Merck & Co. (NYSE: MRK), Zealand Pharma (CPH: ZEAL), Hanmi Pharmaceutical (KRX: 128940), Inventiva Pharma (EPA: IVA), CytoDyn (OTCQB: CYDY), Sagimet Biosciences (NASDAQ: SGMT).
Key Pipeline Metabolic Dysfunction-Associated Steatohepatitis Therapies: Lanifibranor (IVA337), Semaglutide, Azemiglitazone (MSDC-0602K), Efruxifermin (EFX), BIO89-100 (Pegozafermin), Survodutide (BI 456906), GR-MD-02 (Belapectin), LPCN1144, VK2809, Tirzepatide, BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), HTD1801, Leronlimab (PRO 140), Efinopegdutide, HPG1860, Rencofilstat (CRV431), EYP001 (Vonafexor), Semaglutide/Cilofexor/Firsocostat, PXL065, Saroglitazar Magnesium, Denifanstat (TVB-2640), ION224, Miricorilant (CORT118335), and others
Therapeutic Assessment: Metabolic Dysfunction-Associated Steatohepatitis current marketed and emerging therapies
Metabolic Dysfunction-Associated Steatohepatitis Market Dynamics: Key Market Forecast Assumptions of Emerging Metabolic Dysfunction-Associated Steatohepatitis Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Metabolic Dysfunction-Associated Steatohepatitis Market Access and Reimbursement

Download the report to understand which factors are driving MASH market trends @ Metabolic Dysfunction-Associated Steatohepatitis Market Trends

Table of Contents

1. Key Insights

2. Report Introduction

3. Country-wise MASH Market Overview at a Glance

4. MASH Market Overview by Therapeutic Class

5. Methodology of MASH Epidemiology and Market

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. MASH Epidemiology and Patient Population

10. MASH Patient Journey

11. Marketed MASH Drugs

12. Emerging MASH Drugs

13. MASH Market Analysis

14. Key Opinion Leaders’ Views

15. SWOT Analysis

16. Unmet needs

17. Market Access and Reimbursement

18. Appendix

19. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MASH Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Patient Pool, MOA, ROA and Companies by DelveInsight

Brenmiller Energy’s Edison Win Exposes the Market Is Sleeping on This Stock-But Expect an Imminent Wake-Up Call ($BNRG)

The energy transition space is full of noise. Headlines are crowded with eye-catching raises, buzzword-laden pitches, and future promises that may or may not materialize. But once in a while, a reality check breaks through the spin. That’s precisely what happened when Brenmiller Energy (NASDAQ: BNRG) earned the Gold at the 2025 Edison Awards for Energy Storage and Management.

For anyone paying attention, that award isn’t just another trophy added to the many already on the shelf—it’s market and technology validation. A clear signal from the industry players who know that Brenmiller’s bGen™ system isn’t just an ambitious project; it’s commercially viable, deployed, and already reshaping the rules for how thermal energy can be stored, distributed, and monetized.

More to the point—while most “competitors” are still pitching decks or refining their R&D slides, Brenmiller is live. That matters more than ever in an industry long on ambition but short on delivery. And the Edison Award isn’t handed out for ideas—it’s earned by execution.

The Market’s Blind Spot? Industrial Heat.

Let’s call it as it is: Heat contributes to over half the global energy equation, yet it’s consistently sidelined in clean energy conversations. While batteries, EVs, hydrogen, and solar panels dominate attention spans and capital flows, industrial process heat accounts for massive global energy consumption, noting that heat touches about 60% of manufactured products. And electrification can’t scale to meet that load—certainly not cleanly and affordably.

Here’s where bGen™ is at its best. Brenmiller isn’t trying to position its system to be the next lithium-ion competitor. It’s carving out the lane where others aren’t even looking—grid-resilient, grid-enhancing, low-emission thermal energy delivered precisely when and where needed. By storing heat from renewable or low-cost sources like solar, waste heat, or off-peak grid electricity and releasing it on demand, bGen™ bypasses intermittency and, better still, mitigates the need for fossil-fuel-reliant systems.

The better news is that deployment isn’t theoretical. It’s happening right now at Tempo Beverages, a subsidiary of Heineken. Brenmiller’s bGen™ units are being implemented on-site, providing and storing thermal energy that significantly cuts emissions and reduces operating costs while hedging supply chain risk in a geopolitically unstable trade environment.

Again, it’s worth repeating. Unlike any TES sector player we found to evaluate, Brenmiller’s solution isn’t a pilot or a trial. It’s commercial. And it’s providing what the sector needs most—reliability, flexibility, and decarbonization without compromise.

Video Link: https://www.youtube.com/embed/c79CkXIuCwI?si=q7C8My6X62WWn0LN

The Grid Needs More Than Batteries

There’s another storyline here that the market’s overlooking. Grid infrastructure doesn’t just need more battery cells or volatile fuels—it needs more optionality. In that sense, bGen™ isn’t just an industrial asset. It’s a distributed storage solution that can absorb excess renewable generation and feed it back into the system as thermal energy during demand spikes or price surges.

That’s a “grid partnership” play that goes beyond client value—it enhances renewable utilization and load balancing. Moreover, it’s a Heat-as-a-Service model with dual revenue streams, allowing Brenmiller Energy to sell to both industry and infrastructure stakeholders. With cases of grid strain and electrification bottlenecks rising, that positioning alone deserves a premium.

Valuation Disconnect Exposed

We’re not done. Here’s where the story gets even harder to ignore. Companies still chasing proof-of-concept in the thermal storage space—like Rondo Energy—have raised hundreds of millions. Valuations are ballooning on forward-looking narratives.

Not for Brenmiller Energy. At least, not yet. And if any company’s valuation should be surging, it’s theirs. They’re already generating revenue, deploying systems, and earning industry-wide accolades. Yet its market cap hovers around $11 million, and the stock currently trades at around $1.40 per share*. The disconnect between execution and valuation is so wide that it practically dares the market to notice. (*share price on 04/15/25, 10:55 AM EDT)

If you compare apples to apples—or better yet, deployments to promises—BNRG isn’t just undervalued; it’s unreasonably overlooked. Rondo’s latest raise values them in the hundreds of millions. With only ~10M shares outstanding, and based on the valuations given to the privates, BNRG could logically be trading near $50/share, not consolidating below $1.50.

And let’s not forget: Brenmiller Energy is the only public pure-play in thermal energy storage. That matters when institutions finally want exposure to this space. Retail investors may be early, but likely not for long. At a point, valuation disconnects like this get too compelling to ignore.

The Edison Moment Could Be the Catalyst

Know this—the Edison Award isn’t just about recognition. It’s a peer-reviewed statement that says, “This technology works. It’s here. It’s now.” It’s the kind of milestone that can flip a switch in investor perception—particularly among funds, family offices, and ESG-aligned institutional capital searching for proven clean-tech infrastructure.

The irony? Deep-pocketed capital has flooded into private thermal storage startups that haven’t approached the start line. Brenmiller has crossed the finish line. And they’re not stopping. On the contrary, Brenmiller Energy’s mission to deliver decarbonized heat, ease grid congestion, and serve global industrial clients is accelerating. Their tech is on the ground, their revenues are set to soar, and their market footprint is expanding across Europe, the United States, and the Middle East.

All that, and the stock is priced like an idea instead of a functioning infrastructure player. For now, that creates a rare window: a ground-floor opportunity in a space poised to explode, where the technology is real, the clients are multinational, and the path to profitability is visible. Brenmiller Energy’s $500 million project pipeline proves the latter.

Additional Disclaimers and Disclosures:Hawk Point Media Group, LLC. (HPM) has not been compensated to produce and distribute this content. It should be expressly understood that HPM is not operated by a licensed broker, a dealer, or a registered investment adviser. It should also be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. HPM reports/releases are commercial advertisements and are for general information purposes ONLY. The information made available by HPM is not intended to be, nor does it constitute, investment advice or recommendations. The contributors do NOT buy and sell securities covered before or after any particular article, report and/or publication. HPM holds ZERO shares in Brenmiller Energy Ltd. Always do your own due diligence prior to investing in any publicly traded company. While HPM has not been compensated for creating and syndicating this content, HPM discloses having a prior services agreement with the company, and third parties, that expired in April 2025 and 2024, respectively. HPM is a digital marketing and consulting company. Therefore, it is possible that HPM will be retained in the future to create and syndicate digital content for Brenmiller Energy. Accordingly, while fact-based and sourced, our content may portray featured companies in only the most favorable way. A complete disclosure for all services provided and compensated for is linked below. Forward-Looking Statements: This article contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. The forward-looking statements contained or implied in this articcle are subject to other risks and uncertainties, many of which are beyond the control of the Company featured or HPM. Hawk Point Media Group, Llc. undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. For Hawk Point Media Group Llc’s full disclaimer and disclosure statement,clickHERE.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Brenmiller Energy’s Edison Win Exposes the Market Is Sleeping on This Stock-But Expect an Imminent Wake-Up Call ($BNRG)

E-Konomy Pool Service & Supplies Enhances Pool Care Solutions in Tucson

Maintaining a swimming pool requires expertise, the right equipment, and a commitment to keeping water crystal clear year-round. E-Konomy Pool Service & Supplies continues to provide top-tier pool maintenance and repair solutions for residential and commercial pools in Tucson. With decades of experience, the company ensures that pools remain safe, clean, and fully functional in the Arizona climate.

Comprehensive Pool Maintenance for Long-Term Performance

Proper pool maintenance goes beyond aesthetics. Regular care prevents equipment failures, extends the lifespan of pool components, and ensures safe swimming conditions. E-Konomy Pool Service & Supplies offers routine maintenance, chemical balancing, and seasonal preparations to protect pool investments. Using the latest pool care techniques, trained professionals help pool owners avoid costly repairs and unexpected breakdowns.

Reliable Pool Cleaning Services in Tucson

Keeping a pool free from debris, algae, and chemical imbalances requires consistent cleaning and professional oversight. E-Konomy Pool Service & Supplies provides Pool Cleaning Services Tucson to help homeowners and businesses maintain pristine pools. From skimming and vacuuming to filter maintenance and water chemistry adjustments, the company’s cleaning services ensure that pools remain clear and inviting throughout the year.

Expert Swimming Pool Repairs in Tucson

Unexpected pool equipment failures can disrupt pool usage and lead to expensive damage if not addressed promptly. E-Konomy Pool Service & Supplies offers Swimming Pool Repairs Tucson for various issues, including pump malfunctions, filter replacements, and leak detection. Skilled technicians diagnose problems quickly and provide efficient repair solutions to restore pools to optimal working conditions.

A Trusted Pool Service Company in Tucson

Finding a reliable partner for long-term pool maintenance is essential for pool owners. E-Konomy Pool Service & Supplies is recognized as a leading Pool Service Company Tucson. The company offers a full spectrum of services, from routine cleaning to complex repairs. The company’s dedication to high-quality service and customer satisfaction has made it a preferred choice for regional pool owners.

Innovative Pool Solutions for Every Season

The Arizona heat places unique demands on swimming pools, requiring specialized care to handle high temperatures and evaporation rates. E-Konomy Pool Service & Supplies provides tailored solutions for each season, ensuring that pools remain in top condition despite environmental challenges. Advanced water treatment methods, energy-efficient equipment recommendations, and expert troubleshooting keep pools running efficiently.

Commitment to Safety and Efficiency

A properly maintained pool is aesthetically pleasing and safe for swimmers. E-Konomy Pool Service & Supplies prioritizes safety by ensuring that chemical levels are properly balanced, filtration systems function correctly, and all equipment operates at peak efficiency. By addressing potential hazards proactively, the company helps reduce risks associated with pool ownership.

About E-Konomy Pool Service & Supplies

E-Konomy Pool Service & Supplies is a trusted pool maintenance, cleaning, and repair provider in Tucson, AZ. With a team of experienced professionals, the company delivers high-quality solutions to keep pools clean, safe, and fully operational year-round. E-Konomy Pool Service & Supplies is committed to providing exceptional service to residential and commercial pool owners, from routine cleaning to complex equipment repairs.

Media Contact
Company Name: E-Konomy Pool Service & Supplies
Contact Person: Krissandra McNeill
Email: Send Email
Phone: (520) 325-6427
Address:6020 E Speedway Blvd
City: Tucson
State: AZ 85712
Country: United States
Website: http://www.e-konomy.com/

Driving Industrial AI Forward: Composabl’s Multi-Agent Orchestration Platform Now Available on Azure Marketplace

Composabl, a leader in industrial AI multi-agent systems, announces the availability of its software and software integration on the Microsoft Azure Marketplace. Enterprises can now leverage their existing Azure commit credits to purchase the Composabl platform, in return enhancing AI-driven automation and operational efficiency.

Walnut Creek, California – April 15, 2025 – Composabl, Inc., provides an end-to-end SaaS solution for designing, orchestrating, training, benchmarking and deploying multi-agent AI systems in industrial settings. This one-of-a-kind multi-agent AI production and orchestration platform is driving industrial automation into a new era and is now available for purchase on the Microsoft Azure Marketplace. The Azure integration enables industrial enterprises to utilize their pre-purchased Azure commit credits to acquire Composabl’s AI-powered platform and allocate these credits toward training and deploying intelligent AI agents into real-world industrial settings using Azure’s cloud computing infrastructure.

Recognizable industrial use cases cast vision for the art of the possible:

Equipment Calibration: With a virtual AI expert operator, the company took a 6-month chemical machinery calibration process down to a 72-hour changeover.

Glass Bottle Manufacturing: Fully automate a process previously not automated before in this glass manufacturer’s facility, by building a multi-agent system capable of being an expert operator connected to factory floor equipment, including capabilities of making human operator recommendations through the human-to-machine interface (HMI).

Complex Logistics Scheduling: Capture and codify expert operator knowledge and eliminate downtime when expert absences impact the ability to maintain throughput. Company reported that it takes approximately 5 years to onboard and train individuals to achieve expert-level expertise making absenteeism a critical risk in the business.

Cannot view this
image? Visit:
https://wire.newsfilecorp.com/files/9100/246740_53ebd702d49269e4_001.jpg

Composabl Agent Orchestration Studio

Composabl provides an AI multi-agent orchestration studio for industrial applications. The platform enables manufacturers, energy providers, and logistics companies to optimize operations through advanced AI technologies, such as deep learning reinforcement (DRL) and machine learning (ML), as well as AI-powered decision-making, automation, and real-time adaptability in complex environments. By announcing its availability on the Azure Marketplace, Composabl ensures integration with enterprise cloud ecosystems. This allows organizations to scale AI agent deployment with ease.

“I am energized by the fact that we now have AI that can help industrials. Our goal is to provide a comprehensive set of tools that can be applied in the vast amount of use cases in industry, along with sharing knowledge that helps engineers create a more autonomous future on their terms. What sets Composabl apart is that we know engineers have been automating manufacturing for decades. We’re not replacing that expertise—we’re amplifying it. Our methodology-based platform and no-code UI lets engineers themselves orchestrate teams of agents to embed decision intelligence directly into their operations,” said Kence Anderson, CEO at Composabl.

Benefits of Composabl on Azure Marketplace:

Azure Commit Credit Utilization: Enterprises can efficiently allocate pre-purchased Azure commit credits to support AI agent training and deployment without additional budget approvals.
Scalability & Performance: By utilizing Azure’s cloud computing infrastructure, Composabl users can execute high-performance AI agent training and runtime capabilities across distributed industrial operations.
Benchmarking & Optimization: Composabl introduces industry-first guidance (goals, constraints, and success criteria) and benchmarking capabilities that allows engineers to build multi-agents with specialized skills then compare the performance of AI agents.
Physical-World Runtime Features: Composabl provides real-time AI runtime features designed for deployment in physical industrial environments, which provides smooth interaction with factory systems and equipment.

The Composabl platform offers a no-code AI agent orchestration studio, making AI adoption more accessible for engineers and industrial teams without deep programming expertise. To further platform accessibility and the empowerment of industrial engineers Composabl has low-barrier, low-cost, quick-start buying options on the Azure marketplace, including single seat options.

For more information or to purchase Composabl’s AI multi-agent orchestration platform, visit the Microsoft Azure Marketplace.

About Composabl

Composabl is a leading innovator in industrial AI and automation. Built by engineers for engineers, Composabl enables enterprises to enhance operational efficiency, reduce downtime, and increase productivity through AI-powered automation. The platform is designed to deliver real-time intelligence to industrial operations through its runtime features, enabling AI deployment in complex, real-world environments.

For more information, visit www.composabl.com.

Media Contact
Company Name: Composabl, Inc.
Contact Person: Larkin McGowan
Email: Send Email
Country: United States
Website: https://www.composabl.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Driving Industrial AI Forward: Composabl’s Multi-Agent Orchestration Platform Now Available on Azure Marketplace

Music Scam Alert Launches to Protect Artists from Industry Fraud

Music Scam Alert Launches to Protect Artists from Industry Fraud

Music Scam Alert (https://musicscamalert.com/) is proud to announce the launch of its groundbreaking platform dedicated to safeguarding musicians from scams and fraudulent practices in the music industry. With a mission to empower artists and promote transparency, Music Scam Alert provides a vital resource for creators navigating the complex world of music production, promotion, and distribution.

The music industry is a vibrant ecosystem filled with opportunities, but it’s also rife with predatory schemes targeting aspiring and established artists alike. Music Scam Alert addresses this growing issue by offering a comprehensive database of verified information, user-submitted scam reports, and expert guidance to help musicians avoid financial and professional pitfalls.

Key Features of Music Scam Alert:

Scam Database: A regularly updated repository of known scams, including fraudulent promoters, fake streaming services, and shady record deals, sourced from community reports and industry research.
Educational Resources: In-depth guides and articles on spotting red flags, understanding contracts, and protecting intellectual property.
Community Reporting: A secure platform for artists to anonymously share their experiences with suspicious companies or individuals, fostering a collaborative defense against fraud.
Verification Tools: Tips and tools to verify the legitimacy of music-related services, helping artists make informed decisions.

“Music Scam Alert was created to give artists the knowledge and confidence they need to thrive without falling victim to exploitation,” said Erin Wheeler, founder of Music Scam Alert. “We believe that by shining a light on deceptive practices, we can help build a fairer, more trustworthy music industry for everyone.”

The website is designed with user-friendliness in mind, offering an intuitive interface accessible to musicians at all career stages. Whether it’s a bedroom producer signing their first distribution deal or a touring band evaluating a management offer, Music Scam Alert equips artists with the tools to protect their craft and livelihood.

Music Scam Alert invites artists, industry professionals, and supporters to join its growing community. By sharing experiences and spreading awareness, users can contribute to a safer creative environment for all.

For more information, visit https://musicscamalert.com/

Highlighted SCAM – Boost Collective

Music Scam Alert is a musician-focused platform dedicated to exposing scams and fostering transparency in the music industry. Read our most comprehesive and distrubingly fruadlent story on Boost Collective here: https://musicscamalert.com/2025/03/23/boost-collective/

Media Contact:

https://musicscamalert.com/

Media Contact
Company Name: PR Shouts
Contact Person: Roy Timerian
Email: Send Email
Phone: 1-480-418-5044
Country: United States
Website: http://prshouts.com

Pedral Watches Launches “Watches & Art: The Best of Both Worlds”

A limited-edition capsule collection with Boris Pjanic and REM Straps

Stockholm, Sweden – April 15, 2025 – Pedral Watches is proud to unveil Watches & Art: The Best of Both Worlds—a rare, design-driven capsule collection that unites the precision of mechanical timekeeping with the expressive depth of contemporary art. This collaboration brings together Pedral Watches, artist and independent watch dealer Boris Pjanic, and the renowned artisanal leathermakers REM Straps.

At the centre of the collection are five unique dials, each derived from an original painting by Boris Pjanic. A respected name in the independent watch scene and a lifelong artist, Boris translates his brushstrokes into highly detailed, 3D-printed dial artworks—preserving texture, nuance, and emotion in sculptural form.

Each timepiece is housed in Pedral’s signature Artefact case, celebrated for its refined 39mm proportions and balanced silhouette. Paired with organically tanned, laser-etched leather straps by REM, each watch becomes a wearable expression of craftsmanship and creativity.

Technical upgrades include a Miyota Cal. 9039 automatic movement, regulated in-house to ±10 seconds/day, diamond-cut skeleton hands with heat-blued accents, and hand-applied indices. These enhancements elevate each piece, blending engineering excellence with artistic intent.

This edition is strictly limited—just 29 pieces per dial, each one individually numbered and unique. Early clients will receive a complimentary pair of bespoke REM straps. All watches come with a 1-year international warranty.

Launch Schedule

VIP Pre-Orders Open

Easter Sunday, April 20

– 08:00 — New York (EDT)

– 14:00 — London (BST)

– 20:00 — Hong Kong (HKT)

VIP Access Includes:

• 48-hour early ordering window for subscribers

• Complimentary REM strap set for the first 25 clients

• Priority delivery before public release

Public Sale Opens

April 22 at 16:01 CEST

Closes May 4 at 23:00 CEST — or when sold out

Specifications

• 3D-printed dials based on Boris Pjanic’s original paintings

• In-house regulated Miyota Cal. 9039 automatic movement (±10s/day)

• Diamond-cut skeleton hands with heat-blued accents

• Hand-applied indices and individually numbered casebacks• 39mm Stainless steel Artefact case with scratch-resistant coating (11mm thick, 47.5mm lug-to-lug)

• Integrated 316L stainless steel bracelet with scratch-resistant coating (HV 1200) — Fully articulating solid links — Push-button clasp with on-the-fly micro-adjustment

• Water resistance: 100 meters / 330 feet

• Flat sapphire crystal with internal Super-AR coating

• Screw-down crown• Laser-etched REM strap matched to each dial

• 1-year international warranty

• Carefully packaged with refined essentials: a strap adapter, artisanal leather travel roll, soft polishing cloth, butterfly clasp, warranty card

The Collection

Boris Blue

A soothing tone inspired by Boris’ childhood on the Adriatic coast—fluid, nostalgic, and deeply personal.

Shining Bright Like a Diamond

Painted in a single spontaneous session, this dial glows with movement and colour, catching light like a gem.

Driving Home

Quiet and contemplative—rooted in 1990s memories of night drives and moments of reflection.

Geometry In Play

A dynamic composition balancing freedom and control. Shapes layered with playful, intentional rhythm.Perpetual AutumnA warm, symbolic meditation on memory and change. Textured, thoughtful, and richly emotional.

About Boris Pjanic

Boris Pjanic is an artist, collector, and independent watch dealer known for his expertise in vintage Rolex and bespoke dial creation. With a dual background in fine art and horology, he brings a rare perspective to this collaboration—fusing visual storytelling with mechanical beauty.

About Pedral Watches

Founded in Stockholm, Pedral Watches creates limited-run mechanical timepieces with a strong focus on design, storytelling, and individuality. Each release is a reflection of artistic identity, made to be worn, collected, and remembered.

Press & Media Inquiries

Kevin Pedral Founder, Pedral Watches

hello@pedral.watch

www.pedral.eu

Instagram: @pedralwatches

Media Contact
Company Name: Pedral Watches
Contact Person: Kevin Pedral
Email: Send Email
Country: Sweden
Website: www.pedral.eu

Orlando Home Guys Helps Sellers Protect Their Equity as Florida’s Market Shifts Toward Buyers

Local real estate investors offer fast, flexible solutions as inventory rises and home prices dip in Central Florida.

With the spring and summer real estate season heating up, buyers in Florida are starting to gain the upper hand. In Orlando, average home prices are down $20,000 year-over-year, and listings are sitting longer on the market. Orlando Home Guys, a trusted local home-buying company, is helping sellers stay competitive by offering fast cash deals and hassle-free closings.

According to the Orlando Regional Realtor Association, homes in the Orlando area are averaging 76 days on the market—the longest stretch since 2015. As more inventory becomes available and interest rates stabilize, buyers have more negotiating power than in recent years.

“Right now, many sellers are seeing their homes sit for weeks or even months without serious offers,” said a spokesperson for Orlando Home Guys. “We step in with a guaranteed cash offer so homeowners can skip the showings, skip the fees, and move forward on their terms.”

Local real estate agents are largely unprepared and out of options to help their sellers given the current lack of buyer activity. Many homeowners are still unsure how to navigate the market shift and are turning to alternatives when they need to sell fast. Orlando Home Guys provides an alternative path—buying homes in any condition, with no repairs or open houses required.

The company’s services are especially helpful for:

– Sellers who need to move quickly – Homeowners dealing with financial hardship or property issues – Landlords offloading underperforming rentals – Families settling estates or managing inherited homes

“We understand that not every seller has time to wait for the perfect offer,” the spokesperson added. “Orlando Home Guys was built to make the process simple, respectful, and fast.”

As the Orlando market continues to adjust, Orlando Home Guys remains committed to providing solutions that work for both sides of the transaction. Their all-cash offers and flexible timelines give sellers peace of mind, even as traditional sales become more uncertain.

For more information or to request a no-obligation cash offer, visit OrlandoHomeGuys.com.

About Orlando Home Guys

Orlando Home Guys is a locally owned and operated real estate franchise in Orange County, Florida. They specialize in purchasing homes for cash that need repairs and renovations before they would be ready for a conventional sale.

Media Contact
Company Name: Orlando Home Guys
Contact Person: Alberto Rivera
Email: Send Email
Country: United States
Website: https://orlandohomeguys.com/

Jenni Rae Coaching Introduces Feminine Hustle™: A New Approach to Success for High-Achieving Women

Franklin, TN – April 15, 2025 – Jenni Rae Coaching, a premier coaching and mentorship brand for female entrepreneurs and leaders, is transforming the way women approach business success with Feminine Hustle™—a game-changing methodology that helps high-achieving women build profitable and purpose-driven brands without sacrificing their peace, health, or family.

In a culture that glorifies burnout-driven hustle, Jenni Rae Oates is challenging the status quo: “Hustle isn’t the problem—it’s how you’re hustling that is.”

Feminine Hustle™ introduces a new era of ambition—one that fuels both success and well-being. Designed for women entrepreneurs, coaches, and business leaders, this approach prioritizes internal alignment and purpose with the right strategic action to create sustainable business growth, proving that six-figure and seven-figure success doesn’t have to come at the cost of exhaustion or imbalance.

Jenni Rae’s Story: From Burnout to Breakthrough

For Jenni Rae Oates, success wasn’t always defined by ease and alignment. A former Division I athlete, she learned early on that hard work and high performance could open doors—but she also experienced the downside of “perform-aholism”, where self-worth became tied to achievements.

By her early 20s, Jenni Rae had stepped into roles as a pastor’s wife, mother, and businesswoman, navigating the complexities of building a business while raising a family. With no formal business background, she took a leap of faith into entrepreneurship, determined to create financial freedom and impact.

She succeeded—but at a cost.

After building three successful businesses and training over 20,000 leaders in direct sales, she found herself at a crossroads. She had everything she had worked for—financial security, a thriving business, influence—but she was exhausted, disconnected, and questioning if the “hustle” was worth it.

“I reached a breaking point,” Jenni Rae recalls. “I was making money, but losing myself in the process. I knew there had to be a better way—one that didn’t force me to choose between success and my well-being or family.”

This realization led to years of studying psychology, neuroscience, and peak performance, uncovering what separates top performers from those stuck in endless striving. She discovered that 80% of success isn’t about strategy—it’s about mastering your inner game: mindset, emotional intelligence, and self-leadership.

This became the foundation of her Feminine Hustle™ Method—a new way to work, lead, and build wealth without burnout.

Breaking Free from Toxic Hustle

Many women have been taught that success requires overworking, overcommitting, and overextending themselves. But this “toxic hustle” leaves them feeling undervalued, underpaid, and ultimately, unfulfilled.

“For too long, women have been conditioned to force, stress, and strive their way to success. But whatever you take by force, you have to keep by force. That’s not freedom.”

Jenni Rae’s coaching model shifts the paradigm—helping women scale beyond $500K and beyond while remaining happy, healthy, and whole.

Introducing the Own(h)ers Club and $500K Her Way Challenge

To help women implement the Feminine Hustle™ Method, Jenni Rae Coaching is launching:

● The Own(h)ers Club – A high-performance coaching and mentorship program designed to help women master their inner game, break through success blocks, and build profitable, purpose-driven brands.

● $500K Her Way Challenge (June 23-28, 2025) – A free event guiding women entrepreneurs through the strategies and mindset shifts needed to scale sustainably.

$500K Is Waiting—Hustle a New Way

Women in business no longer have to choose between success and personal fulfillment. With Feminine Hustle™, they can have both.

To download the free guide, visit $500K Her Way – https://bit.ly/500kherwayplaybook. Drop by @‌jenniraeoates to join the movement. For more information, visit www.jennirae.com.

About Jenni Rae Coaching

Jenni Rae Coaching empowers high-achieving women to build profitable, purpose-driven brands without sacrificing their peace, health, or family. Founded by Jenni Rae Oates, a seasoned business coach, speaker, and former Division I athlete, the company specializes in mindset mastery, high-performance coaching, and sustainable business growth. Through the Feminine Hustle™ Method and her 3-day RISE Leader Experience, Jenni Rae helps women break free from toxic hustle culture and scale beyond $500K with alignment and ease. With over 20 years of experience training over 20,000 leaders, Jenni Rae Coaching offers coaching, courses, and community for women ready to thrive in both life and business.

Media Contact
Company Name: Jenni Rae Coaching
Contact Person: Jenni Rae Oates
Email: Send Email
Country: United States
Website: https://www.jennirae.com/